About SOLVO
SOLVO Biotechnology has been the pioneer and leader in the commercialization of membrane transporter technologies, diagnostics and drug discovery assays.
SOLVO Biotechnology has outstanding knowledge on transporters, the widest drug-transporter assay portfolio and the largest R&D Department among its competitors. SOLVO continuously expands its product and service portfolio (with 10-15 new launches annually), based on the latest results in transporter science, the needs of the pharmaceutical industry and the various regulatory agencies such as FDA and EMA. SOLVO’s mainstream products and services are in vitro and in vivo assay systems to detect the interaction of test compounds with a wide array of ABC and SLC Transporter proteins for ADME/Tox research. All major pharma and biotech companies use SOLVO’s assays, either in-house or as contract research.
SOLVO’s vision is to be globally renowned as a scientific leader and high quality provider of products and services in the field of ADME/Tox related transporters.
SOLVO’s mission is to help its customers achieve their goals by providing them with products, services and consulting associated with ADME/Tox related transporters.
SOLVO Biotechnology - “The Transporter Company” is a privately held biopharmaceutical company established in 1999 by a group of pre-eminent scientists working in the areas of ABC transporter proteins and multi-drug resistance at leading Hungarian universities. The company holds patents relating to drug targets and modulators, gene therapy applications and functional aspects of pharmacogenetics.
SOLVO’s product portfolio contains in vitro human and rodent drug transporter assay systems, its own brands such as the membrane-based PREDEASYTM and PREDIVEZTM kits, the unique ready-to-use cellular assay kits: PREDICELLTM and PreadyPortTM , transporter inhibitors and substrates, cell lines for licensing and transporter specific antibodies.
SOLVO’s service portfolio covers contract research services for in vitro drug transporter testing using the widest assay portfolio among its competitors: membrane-based ATPase, and VT assays; dye-transport and monolayer assays, cellular uptake assays. SOLVO’s service provides assays for all efflux and uptake transporters recommended by the FDA. SOLVO is the first and only contract research organization that provides transporter specific in vivo assays: rat brain microdialysis, and rat liver biliary excretion. SOLVO has the most comprehensive competencies in the custom development of new cell lines and assays.
Moreover, SOLVO’s MultiDrugQuantTM Diagnostic Kit detects the level of multidrug resistance caused by MDR1, MRP1 and BCRP activities in tumor cells in ex vivo clinical samples with flow cytometry. This kit is a unique phenotypic-diagnostic test to:
- Help drug developers select the appropriate patient sub-population for the drug - in clinical trials;
- Help physicians select the most effective chemotherapy for the patient and plan personalized treatment protocols = “Theranostics”;
- Help physicians monitor cancer disease progression.
